论文部分内容阅读
目的:研究阿德福韦酯联合苦参素胶囊治疗慢性乙型肝炎的疗效及对乙肝病毒DNA的影响。方法:将86例慢性乙型肝炎患者纳入研究对象,随机分为给予阿德福韦酯联合苦参素胶囊治疗的观察组和单独给予阿德福韦酯治疗的对照组,观察肝功能指标、肝纤维化指标及不良反应例数。结果:观察组患者的ALT(37.8±7.2)U·L-1、AST水平(35.5±6.9)U·L-1、HBV-DNA拷贝数(3.1±0.9)×104及耐药例数(3)、HA(61.3±11.4)ng·ml-1、LN(118.9±13.7)ng·ml-1、ⅣC(74.3±12.8)ng·ml-1、PⅢNP(11.4±2.8)ng·ml-1及不良反应例数(7)明显低于对照组,HBV-DNA转阴例数(42)明显高于对照组(P<0.05)。结论:阿德福韦酯联合苦参素胶囊治疗能够改善肝功能、减少HBV-DNA拷贝数,且安全性理想。
Objective: To study the curative effect of adefovir dipivoxil and oxymatrine capsules on chronic hepatitis B and its effect on hepatitis B virus DNA. Methods: Eighty-six patients with chronic hepatitis B were enrolled into the study. Patients were randomly divided into observation group treated with adefovir dipivoxil and oxymatrine capsule and control group treated with adefovir dipivoxil alone. Liver function parameters, Liver fibrosis indicators and adverse reaction cases. Results: The ALT (37.8 ± 7.2) U · L-1, the AST level (35.5 ± 6.9) U · L-1, the HBV DNA copy number (3.1 ± 0.9) × 104 and the drug resistance (61.3 ± 11.4) ng · ml-1, LN (118.9 ± 13.7) ng · ml-1, ⅣC (74.3 ± 12.8) ng · ml-1 and PⅢNP (11.4 ± 2.8) ng · ml- The number of adverse reactions (7) was significantly lower than that of the control group. The number of HBV-DNA negative cases (42) was significantly higher than that of the control group (P <0.05). Conclusion: Adefovir dipivoxil and oxymatrine capsules can improve liver function and reduce HBV-DNA copy number, and its safety is satisfactory.